Review: Social media use and adolescent mental health - an umbrella review and power analysis.

Child Adolesc Ment HealthJan 27, 2026 (epub)
Clinical ResearchPsychiatry

Katrine B Tølbøll

✦ AI-curated · Sources linked

In 30 seconds

This umbrella review and power analysis synthesized peer-reviewed reviews and meta-analyses published from 2021 to 2025 on social media use (SMU) and mental health in adolescents aged 10–24 years. It included 72 reviews, of which 20 were meta-analyses. General SMU had weak and inconsistent associations with well-being and ill-being, whereas problematic SMU was consistently associated with ill-being. Power analyses of 17 meta-analyses found that all meta-analyses examining problematic SMU and ill-being had median study-level power above 99%; power was less adequate for general SMU and well-being.

Key findings

  • All meta-analyses examining problematic SMU and ill-being had median study-level power above 99%.
  • Only 4 of 15 meta-analyses of general SMU reached median study-level power above 80%.
  • Only 4 meta-analyses examining well-being reached median study-level power above 80%.
  • General SMU showed weak and inconsistent associations with well-being and ill-being; problematic SMU was consistently linked to ill-being.

Why it matters

The review suggests that inconsistent findings about general social media use and adolescent mental health may partly reflect inadequate statistical power, rather than evidence that associations are absent. Distinguishing general from problematic use and improving power in future studies may help clarify which patterns of use relate to mental health outcomes.

What to keep in mind

The power analyses used reported effect sizes from eligible meta-analyses, and the review’s conclusions are limited to the reviews and meta-analyses published between 2021 and 2025.

Source

Published in Child Adolesc Ment Health. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.